Monte Rosa Therapeutics (NASDAQ:GLUE) Downgraded by Wells Fargo & Company to “Equal Weight”
Wells Fargo & Company cut shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Free Report) from an overweight rating to an equal weight rating in a research note released on Thursday morning, MarketBeat reports. The firm currently has $11.00 price target on the stock, down from their prior price target of $14.00. Separately, Wedbush restated an […]
More Stories
VEON (NASDAQ:VEON) Hits New 52-Week High – Time to Buy?
VEON Ltd. (NASDAQ:VEON – Get Free Report)’s share price reached a new 52-week high on Friday . The company traded...
Mila Resources (LON:MILA) Sets New 52-Week Low – Should You Sell?
Shares of Mila Resources Plc (LON:MILA – Get Free Report) reached a new 52-week low during mid-day trading on Friday...
SysGroup (LON:SYS) Sets New 12-Month Low – Should You Sell?
SysGroup plc (LON:SYS – Get Free Report) shares hit a new 52-week low on Friday . The stock traded as...
abrdn Asia Focus (LON:AAS) Reaches New 12-Month High – Time to Buy?
abrdn Asia Focus plc (LON:AAS – Get Free Report) shares hit a new 52-week high during mid-day trading on Friday...
Stellar AfricaGold (CVE:SPX) Stock Price Up 20% – Here’s Why
Shares of Stellar AfricaGold Inc. (CVE:SPX – Get Free Report) were up 20% during trading on Friday . The company...
Omineca Mining and Metals (CVE:OMM) Stock Price Up 40% – Still a Buy?
Omineca Mining and Metals Ltd. (CVE:OMM – Get Free Report)’s share price traded up 40% during mid-day trading on Friday...